Potent Long-Acting Inhibitors Targeting the HIV-1 Capsid Based on a Versatile Quinazolin-4-one Scaffold-Reference-Cited by-同舟云学术

Potent Long-Acting Inhibitors Targeting the HIV-1 Capsid Based on a Versatile Quinazolin-4-one Scaffold

Published:2023-01-31 Issue:3 Volume:66 Page:1941-1954
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Gillis Eric P.¹^ORCID,Parcella Kyle¹^ORCID,Bowsher Michael¹,Cook James H.¹,Iwuagwu Christiana¹,Naidu B. Narasimhulu¹^ORCID,Patel Manoj¹,Peese Kevin¹^ORCID,Huang Haichang²,Valera Lourdes²,Wang Chunfu²,Kieltyka Kasia³,Parker Dawn D.³,Simmermacher Jean³,Arnoult Eric⁴,Nolte Robert T.⁵,Wang Liping⁵,Bender John A.⁶,Frennesson David B.⁷,Saulnier Mark⁶,Wang Alan Xiangdong⁶,Meanwell Nicholas A.⁶^ORCID,Belema Makonen⁶,Hanumegowda Umesh³⁸,Jenkins Susan³,Krystal Mark²,Kadow John F.¹,Cockett Mark⁸,Fridell Robert²

Affiliation:

1. Discovery Chemistry, ViiV Healthcare, Branford, Connecticut 06405, United States

2. Discovery Biology, ViiV Healthcare, Branford, Connecticut 06405, United States

3. Discovery Pharmaceutics, DMPK and Toxicology, ViiV Healthcare, Branford, Connecticut 06405, United States

4. Molecular Design, GSK, Collegeville, Pennsylvania 19426, United States

5. Protein Cellular and Structural Sciences, GSK, Collegeville, Pennsylvania 19426, United States

6. Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development, Princeton, New Jersey 08543, United States

7. Small Molecule Drug Discovery, Bristol Myers Squibb Research and Early Development, Cambridge, Massachusetts 02142, United States

8. ViiV Discovery, ViiV Healthcare, Branford, Connecticut 06405, United States

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.jmedchem.2c01732

Reference40 articles.

1. UNAIDS. https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf (accessed on March 29, 2022).

2. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV

3. HIV-1 capsid variability: viral exploitation and evasion of capsid-binding molecules

4. Image reconstructions of helical assemblies of the HIV-1 CA protein

5. HIV-1 capsid is the key orchestrator of early viral replication

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Insights into the binding mechanism of 2,5‐substituted 4‐pyrone derivatives as therapeutic agents for fused dimeric interactions: A computational study using QTAIM, dynamics and docking simulations of protein–ligand complexes;International Journal of Quantum Chemistry;2024-01-25

2. Identifying Discrepancies in HIV Infectivity and Virion Maturation Using FRET-Based Detection and Quantification;2023-12-26

3. Current drugs for HIV-1: from challenges to potential in HIV/AIDS;Frontiers in Pharmacology;2023-10-26

4. The HIV-1 Capsid-Targeted Inhibitor GSK878 Alters Selection of Target Sites for HIV DNA Integration;AIDS Research and Human Retroviruses;2023-06-07

5. Antiviral Properties of HIV-1 Capsid Inhibitor GSK878;Antimicrobial Agents and Chemotherapy;2023-05-17